Calumet had its Relative Strength (RS) Rating upgraded from 77 to 81 Wednesday.
Looking For The Best Stocks To Buy And Watch? Start Here
IBD's proprietary rating tracks market leadership with a 1 (worst) to 99 (best) score. The score shows how a stock's price behavior over the trailing 52 weeks holds up against all the other stocks in our database.
Over 100 years of market history shows that the top-performing stocks tend to have an 80 or higher RS Rating in the early stages of their moves.
Calumet is not currently offering a proper buying opportunity. See if the stock goes on to build a promising consolidation that could launch a new move.
The company showed 0% earnings growth in its most recent report. Revenue rose -1%. The company is expected to report its latest results on or around Aug. 8.
The company holds the No. 18 rank among its peers in the Oil & Gas-Refining/Marketing industry group. UGI, Targa Resources and Global Partners are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
